New insights into the molecular mechanisms of priming of insulin exocytosis
Exocytosis of insulin vesicles in the pancreatic β-cell involves a sequence of regulated events, whose normal function and efficient adaptation to increased demand are essential for the maintenance of glucose homeostasis. These exocytotic events comprise the trafficking and docking of vesicles to th...
Saved in:
Published in | Diabetes, obesity & metabolism Vol. 9; no. s2; pp. 99 - 108 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Oxford, UK : Blackwell Publishing Ltd
01.11.2007
Blackwell Publishing Ltd |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Exocytosis of insulin vesicles in the pancreatic β-cell involves a sequence of regulated events, whose normal function and efficient adaptation to increased demand are essential for the maintenance of glucose homeostasis. These exocytotic events comprise the trafficking and docking of vesicles to the plasma membrane, followed by fusion triggered by Ca²⁺. Recent studies have unravelled post-docking steps mediated by novel factors, which, by their interactions with soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)- and SNARE-associated proteins, confer the docked vesicles fusion competence. These priming steps define the releasable pool of insulin vesicles, which accounts for the first phase of insulin secretion, and controls the rate at which vesicles are replenished for the second phase of secretion. This article aims to summarize what is currently known about the mechanisms that underlie the priming activity of these proteins, focusing on Munc13, a topic to which we have made some recent contributions. Abnormal glucose homeostasis in type 2 diabetes is because of the failure of islet β-cells to augment insulin secretion sufficiently to compensate for reduced insulin sensitivity. A better understanding of the priming steps may help develop novel approaches to increase insulin secretory capacity and thereby prevent the progression to type 2 diabetes. |
---|---|
Bibliography: | http://dx.doi.org/10.1111/j.1463-1326.2007.00788.x ArticleID:DOM788 ark:/67375/WNG-PLWP1FFH-4 istex:FC616C0C0107DC2BD725AA7CCA78F25A9B6868DD Conflicts of Interest All authors declare no conflicts of interest. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1462-8902 1463-1326 |
DOI: | 10.1111/j.1463-1326.2007.00788.x |